Focal LC defects correlate with occurrence of neuroretinal rim and visual field loss

Article

Focal lamina cribrosa (LC) occurs in conjunction with neuroretinal rim and visual field loss.

Focal lamina cribrosa (LC) occurs in conjunction with neuroretinal rim and visual field loss, claims a study in the Archives of Ophthalmology.

Dr Saman Kiumehr et al., Department of Ophthalmology, New York University School of Medicine, New York, USA, compiled a study on 92 eyes of 46 healthy participants and 45 eyes of 31 participants with glaucoma.

All subjects underwent serial horizontal and vertical enhanced depth imaging of the optic nerve head with optical coherence tomography (OCT). Anterior laminar surface irregularity constituted as focal LC defects and spatial consistency was assessed among focal LC defects, neuroretinal rim thinning/notching and visual field defects.

Although there were no LC defects in the healthy eyes there were 98 focal LC defects with various patterns of severity identified in 34 glaucomatous eyes. In the remaining 11 glaucomatous eyes, seven presented with a deeply excavated optic disc.

In the eyes with LC defects 11 had an acquired pit of the optic nerve and the remaining defects occurred due to neuroretinal rim thinning/notching. The majority of defects occurred in the inferior/inferotemporal far periphery of the LC.

Greater sensitivity loss was found in the eyes with focal LC defects limited to the inferior half of the optic disc. Focal loss of laminar beams in glaucoma could cause an acquired pit of the optic nerve.

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.